EU funds first psychedelics project in Portugal, Netherlands, Czech Republic and Denmark
The European Union (EU) has taken a historic step by funding for the first time a project that uses psychedelics, such as the well-known “magic mushrooms”, to address the treatment of depression, especially in the field of palliative care and for people with various illnesses. This innovative EU-backed project marks a significant milestone in medical research and treatment of mental and physical health conditions. Psychedelics, compounds that alter consciousness, include lysergic acid diethylamide (LSD), psilocybin (found in magic mushrooms), methylenedioxymethamphetamine (MDMA or ecstasy), dimethyltryptamine (DMT) and ayahuasca, among others.